NEJM Publishes Final Results of Global Remdesivir Trial Demonstrating Three Key Clinical Benefits in COVID-19 Patients

As the global pandemic evolved, remdesivir has continued to attract sustained attention from both the medical community and the general public. Previously, preliminary results from the ACTT-1 global clinical trial, sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), demonstrated that remdesivir significantly accelerated recovery time in hospitalized patients with coronavirus disease 2019 (COVID-19).

On October 8, the final report of the ACTT-1 trial was officially published in the New England Journal of Medicine (NEJM), helping us to more comprehensively and clearly understand the impact of the drug remdesivir on patients with COVID-19.

In an open letter, Mr. Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, stated, “The final report provides new information that expands on the benefits of remdesivir, and each result from the study is critical for managing the COVID-19 pandemic and for healthcare providers to communicate with patients in decision-making.”

Source: New England Journal of Medicine

Let us first review the trial design of ACTT-1. This was an adaptive, randomized, double-blind, placebo-controlled, global Phase 3 clinical trial. Enrollment began on February 21, 2020, and ended on April 19, 2020, conducted across 73 clinical sites in multiple countries and regions worldwide. The enrolled patients were hospitalized adults with COVID-19 confirmed by nucleic acid testing and evidence of lower respiratory tract infection. Patients were randomized in a 1:1 ratio. The remdesivir group received treatment for up to 10 days, with an initial dose of 200 mg on day 1, followed by 100 mg once daily; the control group received matched placebo. All patients received supportive care according to the standard practices at their respective hospitals.

In this final report, 1,062 patients were randomized (541 to receive remdesivir and 521 to receive placebo). The final data conveyed three key messages:

1. Remdesivir accelerated patient recovery.The efficacy of remdesivir treatment varies among patients depending on the severity of their condition.

· Overall, the median time to recovery was 10 days in the remdesivir group and 15 days in the placebo group, representing a 29% faster recovery in patients receiving remdesivir.

· Among patients with severe disease, those in the remdesivir group experienced a 31% faster recovery (median time to recovery: 11 days vs. 18 days), and this subgroup accounted for 90.1% of the total trial population.

· Patients whose symptoms at study enrollment were assessed as requiring hospitalization and low-flow oxygen supplementation showed the most pronounced recovery benefit, with a 45% acceleration.

· Patients who received medication earlier recovered faster. Patients treated with remdesivir within 10 days of symptom onset showed a statistically significant 37% acceleration in recovery, whereas those treated more than 10 days after symptom onset exhibited a 20% acceleration that was not statistically significant.

· Remdesivir continued to demonstrate efficacy in accelerating patient recovery, even after accounting for the effects of glucocorticoids or hydroxychloroquine.

2. Remdesivir reduced the risk of disease progression in patients.According to the 8-category ordinal scale for symptom assessment, patients in the remdesivir group had a 50% higher likelihood of clinical improvement on day 15.

3. Throughout the study period, remdesivir demonstrated a trend toward reduced patient mortality.

Among all participants, the mortality rate was 6.7% in the remdesivir group and 11.9% in the placebo group on day 15; on day 29, the mortality rate was 11.4% in the remdesivir group and 15.2% in the placebo group. The risk of death was reduced by 27% in the remdesivir group, but this reduction was not statistically significant.

Notably, among patients who required hospitalization and low-flow oxygen therapy prior to the trial (the largest patient subgroup in the trial, accounting for 40%), the remdesivir group showed a significant 70% reduction in the risk of death.

Furthermore, regarding safety, serious adverse events occurred in 131 (24.6%) of the 532 patients who received remdesivir treatment, and in 163 (31.6%) of the 516 patients who received placebo.

Mr. Daniel O’Day pointed out, “For hospitalized patients with COVID-19, we cannot underestimate the importance of accelerating recovery by 5–7 days.” This not only alleviates the physiological challenges posed by COVID-19 itself but also reduces the risk of secondary infections associated with prolonged hospitalization, thereby easing the emotional burden on patients and their families. Furthermore, reducing disease progression “prevents patients from entering critical stages of deterioration, as survival rates are lower once mechanical ventilation is required.” These patient benefits will likewise translate into conservation of healthcare resources. Moreover, the question of whether remdesivir can reduce COVID-19 mortality has been answered, providing valuable information for clinical practice.

Currently, remdesivir has been approved or granted emergency use authorization for the treatment of COVID-19 in more than 50 countries and regions worldwide. The research team also pointed out in the discussion section of the paper that the current mortality rate of COVID-19 remains high, indicating that antiviral therapy alone is insufficient to treat all patients. Therefore, ongoing studies will continue to evaluate the efficacy of combining remdesivir with immunomodulatory agents; for instance, the ACTT-2 and ACTT-3 trials are assessing its combination with the JAK inhibitor baricitinib or interferon beta-1a. Meanwhile, a variety of therapeutic approaches and combination strategies remain necessary to continuously improve the prognosis of patients with COVID-19.

References:

[1] John H. Beigel, et al., (2020). Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med, DOI: 10.1056/NEJMoa2007764

[2] An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences. Retrieved October 9, 2020, from https://stories.gilead.com/articles/an-open-letter-from-our-chairman-and-ceo-oct-8